Moreover, preclinical and clinical studies have demonstrated that IL-2 can augment the development of immune cells, enhancing their abilities to eliminate cancer cells, particularly in renal cell carcinoma and malignant melanoma. This evidence concerns the gene IL2 and renal cell carcinoma.